A novel method for detecting genetic biomarkers in blood-based liquid biopsies using surface plasmon resonance imaging and magnetic beads shows promise in cancer diagnosis and monitoring

Directly detecting biomarkers in liquid biopsy for diagnosis and personalized treatment plays a crucial role in managing cancer relapse and increasing survival rates. Typically, the standard analysis of circulating tumour DNA requires lengthy isolation, extraction, and amplification steps, leading to sample contamination, longer turnaround time and higher assay costs. Surface plasmon resonance is an emerging and promising technology for rapid and real-time dynamic biomarker monitoring in liquid biopsy. Here, we propose a new SPR imaging biosensing approach to detect tumour DNA circulating in the blood of colorectal cancer patients by exploiting the unique properties of superparamagnetic particles. Micrometer beads functionalized with a biotinylated oligonucleotide can directly capture DNA target sequences bearing single-nucleotide variations of KRAS oncogene in human blood plasma. Mutated and wild-type peptide nucleic acid probes immobilized on an SPR gold surface recognize complementary and non-complementary DNA targets by discriminating a single nucleotide mismatch. The new assay allows for detecting p.G13D mutated DNA in buffer and spiked human plasma at attomolar level (down to 300 copies mL^-1) with minimal sample manipulation and in just a few microliters. The assay was validated using plasma samples from colorectal cancer patients and healthy donors, by discriminating mutated DNA circulating in patients and wild-type DNA found in healthy blood donors. This feature underscores the potential of the liquid biopsy assay as a valuable tool for the diagnosis and monitoring of cancer.